Sign In
Buy PSTX
$9.50
+0 (+0%)
At Close: Apr 04, 2025
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
09:00am, Wednesday, 23'rd Jul 2025
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced the appointment of Kristin Ya
Roche set to finalise $1.5bn Poseida Therapeutics takeover
06:32am, Wednesday, 08'th Jan 2025
Swiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Poseida Therapeutics will be completed on Wednesday. Roche on Wednesday said it had been accepted for p
Roche to complete acquisition of U.S. biopharma company Poseida
01:35am, Wednesday, 08'th Jan 2025
Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp.
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders
09:24am, Friday, 20'th Dec 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Poseida Therapeutics, Inc. (NASDAQ: PSTX) to Roche Holdings, Inc. for $9.00 per share in
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?
10:15am, Friday, 13'th Dec 2024
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellular expansion and persistence across subgroups New preclinical data suppo
Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?
10:56am, Thursday, 28'th Nov 2024
From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pick, as it just reached a key level of support. PSTX's 50-day simple moving average crossed above its 20
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Poseida Ther
Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet
11:00am, Wednesday, 27'th Nov 2024
The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?
10:16am, Wednesday, 27'th Nov 2024
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Poseida Therapeutics, Inc. - PSTX
08:50pm, Tuesday, 26'th Nov 2024
NEW YORK , Nov. 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securit
Poseida shares triple on Tuesday, boosted by Roche collaboration
01:17pm, Tuesday, 26'th Nov 2024
Shares of Poseida Therapeutics Inc (NASDAQ: PSTX) more than tripled this morning after Roche Holding (SWX: ROG) said it will buy the clinical-stage biopharmaceutical company for about $1.5 billion. Ro
Why This Gene-Therapy Company's Stock Is Rising 228%
11:10am, Tuesday, 26'th Nov 2024
Poseida Therapeutics, a cell therapy company, is being acquired by Roche in a $1.5 billion deal.
Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
09:22am, Tuesday, 26'th Nov 2024
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Poseida (Nasdaq: PSTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Roche. Click here to learn how
On Tuesday, Roche Holdings AG RHHBY agreed to acquire Poseida Therapeutics, Inc. PSTX for an equity value of approximately $1.5 billion on a fully diluted basis.
